Proton pump inhibitors, fracture risk and selection bias: three studies, same database, two answers

被引：11

作者：

de Vries, F. ^{[1
,2
,3
,4
]}

van Staa, T. -P. ^{[3
,4
]}

Leufkens, H. G. M. ^{[4
]}

机构：

[1] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, NL-3584 CA Utrecht, Netherlands

[2] Southampton Gen Hosp, MRC Epidemiol Resource Ctr, Southampton SO9 4XY, Hants, England

[3] Med & Healthcare Prod Regulatory Agcy, GPRD, London, England

[4] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands

来源：

OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷 / 05期

基金：

英国医学研究理事会;

关键词：

HIP FRACTURE;

D O I：

10.1007/s00198-010-1323-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1641 / 1642

页数：2

共 6 条

[1] Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates [J].

de Vries, F. ;

Cooper, A. L. ;

Cockle, S. M. ;

van Staa, T-P. ;

Cooper, C. .

OSTEOPOROSIS INTERNATIONAL, 2009, 20 (12) :1989-1998

[2] Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database [J].

de Vries, Frank ;

de Vries, Corinne ;

Cooper, Cyrus ;

Leufkens, Bert ;

van Staa, Tjeerd-Pieter .

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2006, 35 (05) :1301-1308

[3] Proton pump inhibitor use and risk of hip fractures in patients without major risk factors [J].

Kaye, James A. ;

Jick, Hershel .

PHARMACOTHERAPY, 2008, 28 (08) :951-959

[4] Use of protonpump inhibitors and risk of hip fracture [J].

Lalmohamed, A. ;

Pouwels, S. ;

Cooper, C. ;

van Staa, T. ;

Leufkens, B. ;

de Boer, A. ;

de Vries, F. .

BONE, 2009, 44 (02) :S396-S397

[5]

U.S. Food and Drug Administration (FDA), 2010, POSS FRACT RISK HIGH

[6] Long-term proton pump inhibitor therapy and risk of hip fracture [J].

Yang, Yu-Xiao ;

Lewis, James D. ;

Epstein, Solomon ;

Metz, David C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2947-2953

← 1 →